Helixbind, Inc.
Boxborough, MA
- UEI
- C37HLWKKAH69
- CAGE
- 6TH55
- Primary NAICS
- 325413 In-Vitro Diagnostic Substance Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1300 Massachusetts Ave #103, Boxborough, MA 01719, USA
- Website
- helixbind.com
- Founded
- 2013
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 38 Instruments & Related Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Helixbind, Inc., a for-profit biotech company headquartered in Boxborough, Massachusetts, develops rapid molecular diagnostic systems for infectious disease detection and operates exclusively as a federal grant recipient, with no contract prime or subcontractor footprint. All recent federal work flows through project grants from the National Institute of Allergy and Infectious Diseases (NIAID) and related HHS institutes, with zero sub-recipient awards; the company competes on merit in the open market for NIH funding without set-aside posture.
Helixbind's federal research portfolio centers on culture-free, rapid molecular diagnostics for bloodstream infections and related invasive pathogens. The company's core platform, RAPID (Resistance and Pathogen Identification), is a fully automated, sample-to-answer benchtop instrument and single-use cassette system that identifies bacterial and fungal pathogens directly from whole blood within approximately three hours without traditional blood culture methods. The platform incorporates proprietary sample preparation technology that processes multiple milliliters of human blood without centrifugation or filtration, uses synthetic double-stranded DNA invading nucleic acids for single-base-pair specificity, and assays only viable microorganisms. Representative grant work includes a $1,029,859 NIAID award (July 2026, performance through June 2029) to advance an automated molecular diagnostic system for rapid characterization of bloodstream infections directly from whole blood; a prior $31.2 million combined value set of NIAID grants (2022–2024) supporting Phase II and Commercialization Readiness Pilot (CRP) projects for RAPID/BSI, RAPID/LD (Lyme disease detection), RAPID/IE (endocarditis), and RAPID/NEO (neonatal sepsis detection). RAPID/BSI has received FDA Breakthrough Device designation.
Customer concentration is absolute: NIAID accounts for 14 of 19 awards in the portfolio, with the broader NIH system and the National Science Foundation accounting for the remaining five. Performance occurs in Acton, Massachusetts. The vendor's recompete cliff shows five awards reaching ultimate completion within the next twenty-four months. Over the past five years, funding has averaged roughly two awards annually, with volatility across 2021–2024 and one award in 2026; cumulative obligated dollars across all awards total $63.2 million. Helixbind operates without federal contracts, GWACs, BPAs, or vehicles; the entire federal footprint is competitive grant funding for preclinical and early-stage commercial development of molecular diagnostics for sepsis, Lyme disease, endocarditis, and neonatal infections.
Quick answers
Is Helixbind, Inc. registered in SAM.gov?
Yes. Helixbind, Inc.'s SAM.gov registration is active through May 13, 2027.
What is Helixbind, Inc.'s CAGE code?
Helixbind, Inc.'s CAGE code is 6TH55, and its Unique Entity ID (UEI) is C37HLWKKAH69.
What is Helixbind, Inc.'s most recent federal award?
Helixbind, Inc.'s most recent federal grant award is Automated system for the direct from blood characterization of bloodstream infections (R44AI197309), from National Institute of Allergy and Infectious Diseases (NIH), on July 16, 2026.
On GovTribe
See Helixbind, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors